Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
- PR Newswire
Changes to Sobi's management
Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire. Dr Hoos brings more than three decades of experience from the global pharmaceutical industry, including positions at Amgen, GSK and Aventis and most recently as a member of the board of Patient Focused Medicine Development, a non-profit organisation dedicated to bringing the voice of patients into the development of medicines. Similar t
- PR Newswire
Invitation: Sobi's Q4 and FY 2022 report
Sobi plans to publish its report for the fourth quarter and full year of 2022 on 8 February 2023 at 08:00 CET.
- PR Newswire
NEJM publishes data demonstrating clinically meaningful prevention of bleeds and superior bleed protection for efanesoctocog alfa
Pivotal study data published in The New England Journal of Medicine (NEJM) continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa (formerly BIVV001), a potential new medicine for haemophilia A. These data demonstrate the clinical benefits of normal to near-normal factor activity levels (>40%) for the majority of the week achieved by once weekly efanesoctocog alfa dosing. Efanesoctocog alfa is currently under priority regulatory review in the US with a targ
